JP2007533733A - 食物摂取管理の方法 - Google Patents

食物摂取管理の方法 Download PDF

Info

Publication number
JP2007533733A
JP2007533733A JP2007509061A JP2007509061A JP2007533733A JP 2007533733 A JP2007533733 A JP 2007533733A JP 2007509061 A JP2007509061 A JP 2007509061A JP 2007509061 A JP2007509061 A JP 2007509061A JP 2007533733 A JP2007533733 A JP 2007533733A
Authority
JP
Japan
Prior art keywords
route
subject
betahistine
agonist
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007509061A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007533733A5 (https=
Inventor
ニル バラク，
Original Assignee
モル リサーチ アプリケーションズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL16159504A external-priority patent/IL161595A0/xx
Application filed by モル リサーチ アプリケーションズ リミテッド filed Critical モル リサーチ アプリケーションズ リミテッド
Publication of JP2007533733A publication Critical patent/JP2007533733A/ja
Publication of JP2007533733A5 publication Critical patent/JP2007533733A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2007509061A 2004-04-22 2005-04-21 食物摂取管理の方法 Pending JP2007533733A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL16159504A IL161595A0 (en) 2004-04-22 2004-04-22 Betahistine as a weight management agent
US67029005P 2005-04-12 2005-04-12
PCT/IL2005/000440 WO2005101979A2 (en) 2004-04-22 2005-04-21 Method of food intake management

Publications (2)

Publication Number Publication Date
JP2007533733A true JP2007533733A (ja) 2007-11-22
JP2007533733A5 JP2007533733A5 (https=) 2008-05-29

Family

ID=35197421

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007509061A Pending JP2007533733A (ja) 2004-04-22 2005-04-21 食物摂取管理の方法

Country Status (10)

Country Link
US (5) US7737165B2 (https=)
EP (1) EP1737454A4 (https=)
JP (1) JP2007533733A (https=)
KR (1) KR20060134041A (https=)
BR (1) BRPI0506807A (https=)
CA (1) CA2553309A1 (https=)
EA (1) EA200601414A1 (https=)
IL (1) IL176793A0 (https=)
NO (1) NO20063221L (https=)
WO (1) WO2005101979A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020506930A (ja) * 2017-02-02 2020-03-05 オトラーヌム アーゲー ベタヒスチンを含む鼻腔内組成物

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
US20080051440A1 (en) * 2004-04-22 2008-02-28 Mor Research Applications Ltd. Compositions for weight management
BRPI0506807A (pt) * 2004-04-22 2007-05-29 Mor Research Applic Ltd método de gerenciamento de consumo de alimento e composição farmacológica
WO2007020079A2 (en) * 2005-08-17 2007-02-22 Synthon B.V. Orally disintegratable simvastatin tablets
US8242148B2 (en) * 2005-12-23 2012-08-14 Nelson Erik B Treatment methods employing histamine H3 receptor antagonists, including betahistine
UA98938C2 (ru) * 2006-06-16 2012-07-10 Теракос, Инк. Лечение психологических состояний с применением антагонистов мускариновых рецепторов м1
US8748419B2 (en) * 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US20080033019A1 (en) * 2006-08-07 2008-02-07 Duke University Cholesterol lowering drug combination
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP3788877B1 (en) * 2007-04-11 2024-08-07 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP2167096A4 (en) * 2007-06-13 2010-07-14 Cypress Bioscience Inc IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM
JP5513378B2 (ja) * 2007-06-15 2014-06-04 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイテッド 治療化合物
KR101621726B1 (ko) 2008-05-27 2016-05-17 더 유니버시티 오브 멜버른 유스타키오관 기능장애 치료용 국소 약학적 조성물
US20120115778A1 (en) * 2009-07-15 2012-05-10 The Trustees Of Columbia University In The City Of New York Methods of Suppressing Appetite by the Administration of Antagonists of the Serotonin HTR1a or HTR2b Receptors or Inhibitors of TPH2
US20110021507A1 (en) * 2009-07-22 2011-01-27 Theracos, Inc. Inhibiting antipsychotic-induced weight gain
JP2013507713A (ja) * 2009-10-13 2013-03-04 ネステク ソシエテ アノニム 食物摂取を評定するシステム及びそのシステムを使用する方法
TR201908514T4 (tr) 2009-12-04 2019-07-22 Alkermes Pharma Ireland Ltd İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇
US20110143704A1 (en) 2009-12-14 2011-06-16 William Lorentz Specialized dial a chip
US8778960B2 (en) * 2010-08-23 2014-07-15 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US20140072936A1 (en) * 2012-09-07 2014-03-13 Patrick D. Herron Method of Tracking Consumption and Associated Effects
ES2770978T3 (es) 2013-05-24 2020-07-06 Alkermes Pharma Ireland Ltd Análogos de morfanos y morfinanos y métodos de uso
EP3003311A2 (en) 2013-05-24 2016-04-13 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
RU2540911C2 (ru) * 2013-06-11 2015-02-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации Способ коррекции синдрома ночной еды у пациентов с тревожно-депрессивными расстройствами
DE102015202695A1 (de) * 2015-02-13 2016-08-18 Carl Zeiss Smt Gmbh Prüfvorrichtung sowie Verfahren zum Prüfen eines Spiegels
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet
KR20250154480A (ko) * 2023-02-28 2025-10-28 바이오하벤 테라퓨틱스 리미티드 강박 관련 장애, 틱 장애 및 글루타메이트 흥분독성 관련 장애의 치료 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55154915A (en) * 1979-05-21 1980-12-02 Jiyan Sadeia Shieruki Medicine mold
JP2003500353A (ja) * 1999-05-19 2003-01-07 アストラゼネカ・アクチエボラーグ 処置方法
JP2003528829A (ja) * 2000-03-08 2003-09-30 アーヴェーデー．ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト 薬剤学的製剤
JP2004501957A (ja) * 2000-06-29 2004-01-22 レナーツ，ビンセンツ 徐放性医薬製剤に利用する架橋高アミローススターチとその製造方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1577871A (en) * 1976-05-28 1980-10-29 Unimed Inc Prevention of myocardial infarction
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
DE69939027D1 (de) * 1998-12-23 2008-08-14 Maxim Pharm Inc Synthese von histamin-dihydrochlorid
DE69911058T2 (de) 1998-12-23 2004-06-03 G.D. Searle Llc, Chicago Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen
IT1309591B1 (it) 1999-03-05 2002-01-24 Formenti Farmaceutici Spa Composizioni a rilascio controllato di betaistina.
WO2002087556A2 (en) 2001-04-11 2002-11-07 Atherogenics, Inc. Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
US20030162824A1 (en) 2001-11-12 2003-08-28 Krul Elaine S. Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
AU2003266165A1 (en) 2002-09-13 2004-04-30 Hossein Dovlatabadi Methods and compositons for the use of d-malic acid to decrease serum triglyceride, cholesterol, and lipoprotein levels
US20050222175A1 (en) 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
US20080051440A1 (en) * 2004-04-22 2008-02-28 Mor Research Applications Ltd. Compositions for weight management
BRPI0506807A (pt) * 2004-04-22 2007-05-29 Mor Research Applic Ltd método de gerenciamento de consumo de alimento e composição farmacológica
US20060039867A1 (en) 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders with setiptiline

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55154915A (en) * 1979-05-21 1980-12-02 Jiyan Sadeia Shieruki Medicine mold
JP2003500353A (ja) * 1999-05-19 2003-01-07 アストラゼネカ・アクチエボラーグ 処置方法
JP2003528829A (ja) * 2000-03-08 2003-09-30 アーヴェーデー．ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト 薬剤学的製剤
JP2004501957A (ja) * 2000-06-29 2004-01-22 レナーツ，ビンセンツ 徐放性医薬製剤に利用する架橋高アミローススターチとその製造方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN5007006067, ＲＯＳＳＩ, ＰＨＹＳＩＯＬＯＧＹ ＆ ＢＥＨＡＶＩＯＩＲ, 1999, Ｖ６６ Ｎ３, Ｐ５１７−５２１ *
JPN5007006068, ＳＺＥＬＡＧ, ＰＯＬＩＳＨ ＪＯＵＲＮＡＬ ＯＦ ＰＨＡＲＭＡＣＯＬＯＧＹ．, 2001, Ｖ５３, Ｐ７０１−７０７ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020506930A (ja) * 2017-02-02 2020-03-05 オトラーヌム アーゲー ベタヒスチンを含む鼻腔内組成物

Also Published As

Publication number Publication date
US20080004322A1 (en) 2008-01-03
WO2005101979A3 (en) 2006-07-27
WO2005101979A2 (en) 2005-11-03
EP1737454A2 (en) 2007-01-03
US20060073217A1 (en) 2006-04-06
CA2553309A1 (en) 2005-11-03
US7737165B2 (en) 2010-06-15
US20080004324A1 (en) 2008-01-03
EP1737454A4 (en) 2007-08-08
US20060084686A1 (en) 2006-04-20
IL176793A0 (en) 2006-10-31
BRPI0506807A (pt) 2007-05-29
NO20063221L (no) 2006-10-06
US20080051439A1 (en) 2008-02-28
KR20060134041A (ko) 2006-12-27
EA200601414A1 (ru) 2007-02-27

Similar Documents

Publication Publication Date Title
JP2007533733A (ja) 食物摂取管理の方法
US20100152161A1 (en) Compositions for weight management
US7834056B2 (en) Pharmaceutical composition for gout
ES2654787T3 (es) Formulación farmacéutica disponible por vía oral adecuada para la gestión mejorada de trastornos del movimiento
BRPI0914985B1 (pt) Composição para administração oral de baixa dose de topiramato/fentermina
JPH05507731A (ja) 物質乱用障害の治療用医薬組成物
TW201136916A (en) New uses
EA003142B1 (ru) Лекарственное средство, обладающее антидепрессивным действием, его применение и способ лечения
WO2004080444A2 (en) Methods for treating lower urinary tract disorders and the related disorders vulvodynia and vulvar vestibulitis using cav2.2 subunit calcium channel modulators
EP0923370A2 (en) Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
TWI228040B (en) Pharmaceutical compositions comprising tramadol
AU758181B2 (en) Therapeutic agents
JPS59193821A (ja) 抗不安薬としてのフルオキセチンの使用法
CN108463224A (zh) sGC刺激剂用于胃肠功能障碍治疗的应用
WO2014199294A1 (en) Pharmaceutical combinations of a pi3k inhibitor and a microtubule destabilizing agent
TWI302912B (en) Therapeutic use
CN101610760A (zh) 恶病质的治疗
US7223754B2 (en) Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders
US20080051440A1 (en) Compositions for weight management
JP2026505506A (ja) 癌を処置するためのｔｅａｄ及びｋｒａｓ ｇ１２ｄ阻害剤の組み合わせ
TW567068B (en) Medicinal compositions for treating lower uropathy
MX2010006520A (es) Metodo y composicion para el tratamiento de una condicion mediada por alfa-adrenoceptor.
Aminoff Basic & Clinical Pharmacology
AU2006202950A1 (en) Methods and Compositions for Weight Management
MXPA06007693A (en) Method of food intake management

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110628